Jean Baptiste Bachet

Summary

Country: France

Publications

  1. doi request reprint [What is the contribution of tumor response in colorectal cancer?]
    Jean Baptiste Bachet
    Universite Pierre et Marie Curie, Paris VI, Assistance Publique Hopitaux de Paris, Groupe Hospitalier de la Pitié Salpêtrière, Service d Hepato gastro enterologie, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Bull Cancer 100:743-55. 2013
  2. doi request reprint S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
    Jean Baptiste Bachet
    Medical University Pierre et Marie Curie, UFR Paris VI, 91 105 boulevard de l Hôpital, Paris, France
    Eur J Cancer 49:2643-53. 2013
  3. doi request reprint Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
    J B Bachet
    Medical University Pierre et Marie Curie, UFR Paris VI, Paris
    Ann Oncol 23:2327-35. 2012
  4. pmc Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor
    Marc Antoine Allard
    EA4340, Versailles SQY University, Boulogne, France
    Diagn Pathol 7:156. 2012
  5. doi request reprint Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
  6. ncbi request reprint Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
    Geraldine Perkins
    Institut National de la Recherche et de la Santé Médicale, UMR S775, Paris, France
    Int J Cancer 127:1321-31. 2010
  7. doi request reprint Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Tre
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 30:3353-60. 2012
  8. doi request reprint [Cutaneous adverse reactions of EGFR (epidermal growth factor receptor)-inhibitors: therapeutic algorithm of the French PROCUR group]
    Claude Bachmeyer
    Assistance Publique Hopitaux de Paris, Hopital Tenon, Service de Medecine Interne, 4, rue de la Chine, 75020 Paris, France
    Bull Cancer 100:417-26. 2013
  9. ncbi request reprint Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13
    Jean Baptiste Bachet
    EA4340 Epidémiologie et Oncogénesè des Tumeurs Digestives, Versailles Saint Quentin en Yvelines University, 78280 Guyancourt, France Hepato Gastroenterology Department, Pitie Salpetriere Hospital, 75013 Paris, France Medical University Pierre et Marie Curie, UFR Paris VI, France
    Eur J Cancer 49:2531-41. 2013
  10. pmc Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Astrid Lievre
    Gastroenterology and Digestive Oncology Unit, Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne Billancourt, France
    BMC Cancer 9:347. 2009

Detail Information

Publications14

  1. doi request reprint [What is the contribution of tumor response in colorectal cancer?]
    Jean Baptiste Bachet
    Universite Pierre et Marie Curie, Paris VI, Assistance Publique Hopitaux de Paris, Groupe Hospitalier de la Pitié Salpêtrière, Service d Hepato gastro enterologie, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Bull Cancer 100:743-55. 2013
    ..Finally, although there is no high-level of evidence, tumor response has prognostic value for metastases resection in mCRC and is a therapeutic objective in patients with potentially resectable metastases or symptomatic advanced disease...
  2. doi request reprint S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
    Jean Baptiste Bachet
    Medical University Pierre et Marie Curie, UFR Paris VI, 91 105 boulevard de l Hôpital, Paris, France
    Eur J Cancer 49:2643-53. 2013
    ..S100A2 has been recently suggested as a negative prognostic biomarker in PAC. We aimed to investigate its prognostic and/or predictive value in a large independent multicentric cohort of patients with resected PAC...
  3. doi request reprint Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
    J B Bachet
    Medical University Pierre et Marie Curie, UFR Paris VI, Paris
    Ann Oncol 23:2327-35. 2012
    ..Many prognostic biomarkers have been tested, but most studies included heterogeneous patients. We aimed to investigate the prognostic and/or predictive values of four relevant biomarkers in a multicentric cohort of patients...
  4. pmc Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor
    Marc Antoine Allard
    EA4340, Versailles SQY University, Boulogne, France
    Diagn Pathol 7:156. 2012
    ..However, lymphoid infiltration is heterogeneous and the reproducibility of quantification based on single counts within a tumor is very low. We aimed to develop a reproducible method for evaluating lymphoid infiltration in tumors...
  5. doi request reprint Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy...
  6. ncbi request reprint Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
    Geraldine Perkins
    Institut National de la Recherche et de la Santé Médicale, UMR S775, Paris, France
    Int J Cancer 127:1321-31. 2010
    ..Our results suggest the importance of EGFR downstream signaling phosphoproteins expression in addition to KRAS status to define the subgroup of patients who will not benefit from anti-EGFR therapy...
  7. doi request reprint Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Tre
    Christophe Tournigand
    Hopital Saint Antoine, Paris, France
    J Clin Oncol 30:3353-60. 2012
    ..Oxaliplatin combined with fluoropyrimidine improves survival in patients with stage III colon cancer. However, adjuvant chemotherapy with oxaliplatin is controversial in stage II and elderly patients...
  8. doi request reprint [Cutaneous adverse reactions of EGFR (epidermal growth factor receptor)-inhibitors: therapeutic algorithm of the French PROCUR group]
    Claude Bachmeyer
    Assistance Publique Hopitaux de Paris, Hopital Tenon, Service de Medecine Interne, 4, rue de la Chine, 75020 Paris, France
    Bull Cancer 100:417-26. 2013
    ..This multidisciplinary study should facilitate the standardised, optimised management of skin toxicity associated with EGFR-inhibitors...
  9. ncbi request reprint Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13
    Jean Baptiste Bachet
    EA4340 Epidémiologie et Oncogénesè des Tumeurs Digestives, Versailles Saint Quentin en Yvelines University, 78280 Guyancourt, France Hepato Gastroenterology Department, Pitie Salpetriere Hospital, 75013 Paris, France Medical University Pierre et Marie Curie, UFR Paris VI, France
    Eur J Cancer 49:2531-41. 2013
    ..Identification of kindreds with KIT or PDGFRA germline mutation raised new questions, especially regarding the diagnosis, management, monitoring and treatment of these patients...
  10. pmc Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Astrid Lievre
    Gastroenterology and Digestive Oncology Unit, Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne Billancourt, France
    BMC Cancer 9:347. 2009
    ..The aim of this study was to evaluate the activity of bevacizumab combined with FOLFIRI or FOLFOX in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin...
  11. doi request reprint From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer
    Aimery de Gramont
    Service d Oncologie Medicale, Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Paris, France
    Semin Oncol 38:521-32. 2011
    ..Clarity regarding the clinical signal needed before launching a phase III study and optimized designs adapted to multiple agents are urgently needed for new trials...
  12. pmc Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review
    Jean Baptiste Bachet
    Department of Hepato gastro enterology, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Universite Pierre and Marie Curie, Paris, France
    Oncologist 17:555-68. 2012
    ..Variations in terms of the treatment-related incidence and intensity have not been fully elucidated. Tetracyclines have been recommended for the prophylaxis and treatment of folliculitis but their efficacy is yet to be established...
  13. ncbi request reprint Echocardiographic follow-up of treated patients with carcinoid syndrome
    Nicolas Mansencal
    Department of Cardiology, Universite de Versailles Saint Quentin, Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne, France
    Am J Cardiol 105:1588-91. 2010
    ..Carcinoid heart disease progresses over time, highlighting the need for echocardiographic follow-up once carcinoid syndrome has been diagnosed...
  14. ncbi request reprint KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Astrid Lievre
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale UMR 775, Paris, France
    Cancer Res 66:3992-5. 2006
    ..The EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment...